Candel Therapeutics, Inc. CADL Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $30.5M+57.9% | $19.31M-21.2% | $24.51M+17.9% | $20.79M+37.1% | ||
| $17.77M+26.4% | $14.06M+1.2% | $13.89M-1.2% | $14.06M+31.5% | ||
| $48.27M+44.6% | $33.37M-13.1% | $38.39M+10.2% | $34.85M+34.8% | ||
| -$48.27M-44.6% | -$33.37M+13.1% | -$38.39M-10.6% | -$34.72M-35.0% | ||
| $2.12M+1.4% | $2.09M-19.5% | $2.6M+51.9% | $1.71M— | ||
| —— | -$21.81M— | —— | $15.93M— | ||
| -$38.18M+30.8% | -$55.18M-45.4% | -$37.94M-102% | -$18.79M+50.2% | ||
| -$0.72+58.6% | -$1.74-33.8% | -$1.30-103% | -$0.64— | ||
| -$47.46M-46.1% | -$32.48M+13.3% | -$37.48M-10.4% | -$33.94M-33.1% | ||
| -$48.27M-44.6% | -$33.37M+13.1% | -$38.39M-10.6% | -$34.72M-35.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Candel Therapeutics, Inc.'s revenue?
- Candel Therapeutics, Inc. (CADL) generated $124.0K in revenue over the trailing twelve months.
- Is Candel Therapeutics, Inc. profitable?
- Candel Therapeutics, Inc. is not currently profitable: it reported a net loss of $54.4M over the trailing twelve months, a -15156.5% net margin.
- What is Candel Therapeutics, Inc.'s earnings per share?
- Candel Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.99.
- Where does Candel Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Candel Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
